Omicron surge and the future of COVID-19 vaccinations
DOI:
https://doi.org/10.13181/mji.bc.226066Keywords:
COVID-19 vaccine, Omicron, SARS-CoV-2 vaccineAbstract
The global surge of Omicron has caused significant concern. Omicron has caused new wave of infections in nations with adequate vaccine coverage. Omicron has around 30 mutations that are similar to the previous variant of concerns, possibly decreasing vaccine effectiveness (VE). Hence, the emergence of Omicron is predicted to be a significant public health challenge and may alter the future of COVID-19 vaccinations. Furthermore, other issues may affect vaccine policy in the future such as the never-ending vaccine inequity, waning immunity of current COVID-19 vaccines, decreasing VE against new emerging strains, and new findings regarding hybrid immunity. This literature review aimed to explore the possible steps forward using the most updated knowledge on COVID-19 vaccines and Omicron.
Downloads
References
Center for Disease Control and Prevention. Potential rapid increase of Omicron variant infections in the United States. Center for Disease Control and Prevention; 2021.
Mahase E. Covid-19: what do we know about Omicron sublineages? BMJ. 2022;376:o358. https://doi.org/10.1136/bmj.o358
Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis [Internet]. medRxiv [Preprint]. 2021. [posted 2021 Sep 26 cited 2022 Apr 5]. https://doi.org/10.1101/2021.09.23.21264048
Hamady A, Lee J, Loboda ZA. Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses? Infection. 2022;50(1):11-25. https://doi.org/10.1007/s15010-021-01664-z
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. https://doi.org/10.1056/NEJMoa2114583
Hayawi K, Shahriar S, Serhani MA, Alashwal H, Masud MM. Vaccine versus variants (3Vs): are the COVID-19 vaccines effective against the variants? A systematic review. Vaccines. 2021;9(11):1305. https://doi.org/10.3390/vaccines9111305
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626-36. https://doi.org/10.1038/s41577-021-00592-1
Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386(2):116-27. https://doi.org/10.1056/NEJMoa2116063
Leung K, Wu JT. Managing waning vaccine protection against SARS-CoV-2 variants. Lancet. 2022;399(10319):2-3. https://doi.org/10.1016/S0140-6736(21)02841-5
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60. https://doi.org/10.1016/j.ijid.2021.11.009
Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by covid-19 vaccines. N Engl J Med. 2022;386(4):340-50. https://doi.org/10.1056/NEJMoa2115481
Sheikh A, Kerr S, Woolhouse M, Mcmenamin J, Robertson C. Severity of Omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland [Internet]. The University of Edindurgh. [Preprint]. 2021. Available from: https://www.research.ed.ac.uk/en/publications/severity-of-omicron-variant-of-concern-and-vaccine-effectiveness.
Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-46. https://doi.org/10.1016/S0140-6736(22)00017-4
Christie B. Covid-19: early studies give hope Omicron is milder than other variants. BMJ. 2021;375:n3144. https://doi.org/10.1136/bmj.n3144
Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386(5):494-6. https://doi.org/10.1056/NEJMc2119270
Mahase E. Covid-19: Omicron and the need for boosters. BMJ. 2021;375:n3079. https://doi.org/10.1136/bmj.n3079
Khan NA, Al-Thani H, El-Menyar A. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Med Infect Dis. 2022;45:102246. https://doi.org/10.1016/j.tmaid.2021.102246
Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron. Nature. 2022;603:493-6. https://doi.org/10.1038/s41586-022-04465-y
Hart JD, Chokephaibulkit K, Mayxay M, Ong-Lim ALT, Saketa ST, Russell FM. COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron. Lancet Reg Health West Pac. 2022:100404. https://doi.org/10.1016/j.lanwpc.2022.100404
Putri SA. Mix-and-match, which covid-19 booster shot should I get? [Internet]. Jakarta's COVID-19 Response Team. 2022 [cited 2022 Mar 13]. Available from: https://corona.jakarta.go.id/en/artikel/cara-memilih-vaksin-booster-yang-tepat.
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421-30. https://doi.org/10.1056/NEJMoa2115926
Rae M. Omicron: a failure to act with a global focus will continue the proliferation of new variants of covid-19. BMJ. 2021;375:n3095. https://doi.org/10.1136/bmj.n3095
Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib HA, et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA. 2021;326(19):1930-9. https://doi.org/10.1001/jama.2021.19623
Shenoy P, Ahmed S, Paul A, Cherian S, Umesh R, Shenoy V, et al. Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Lancet Rheumatol. 2022;4(2):e80-2. https://doi.org/10.1016/S2665-9913(21)00356-8
Callaway E. COVID super-immunity: one of the pandemic's great puzzles. Nature. 2021;598(7881):393-4. https://doi.org/10.1038/d41586-021-02795-x
Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7(68):eabn8014. https://doi.org/10.1126/sciimmunol.abn8014
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
